Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Reiterated by Zacks Investment Research

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “hold” rating restated by Zacks Investment Research in a report issued on Saturday, Zacks.com reports.

According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “

Several other research firms have also weighed in on YMAB. Wedbush assumed coverage on Y-mAbs Therapeutics in a research report on Tuesday, September 3rd. They set an “outperform” rating and a $38.00 price target on the stock. HC Wainwright set a $40.00 price target on Y-mAbs Therapeutics and gave the company a “buy” rating in a research report on Monday, August 26th. Finally, Cowen reissued a “buy” rating on shares of Y-mAbs Therapeutics in a research report on Monday, July 1st. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $32.50.

Shares of Y-mAbs Therapeutics stock traded up $0.98 on Friday, reaching $26.05. 141,713 shares of the company were exchanged, compared to its average volume of 174,397. The stock has a fifty day moving average price of $27.41 and a 200-day moving average price of $24.29. The firm has a market capitalization of $864.84 million and a price-to-earnings ratio of -17.37. The company has a current ratio of 9.04, a quick ratio of 9.04 and a debt-to-equity ratio of 0.02. Y-mAbs Therapeutics has a fifty-two week low of $15.17 and a fifty-two week high of $32.27.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Wednesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05). On average, equities analysts anticipate that Y-mAbs Therapeutics will post -2.1 earnings per share for the current fiscal year.

In related news, Director Johan Wedell-Wedellsborg sold 89,166 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $26.58, for a total transaction of $2,370,032.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Thomas Gad sold 4,000 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $25.21, for a total value of $100,840.00. Insiders have sold 348,010 shares of company stock worth $9,425,028 over the last three months. 38.40% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of YMAB. TD Asset Management Inc. raised its position in Y-mAbs Therapeutics by 11.5% during the second quarter. TD Asset Management Inc. now owns 25,453 shares of the company’s stock valued at $582,000 after buying an additional 2,624 shares during the period. Swiss National Bank purchased a new position in Y-mAbs Therapeutics in the second quarter valued at about $290,000. Wells Fargo & Company MN grew its stake in Y-mAbs Therapeutics by 422.2% in the second quarter. Wells Fargo & Company MN now owns 19,203 shares of the company’s stock valued at $438,000 after purchasing an additional 15,526 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Y-mAbs Therapeutics by 10.4% in the second quarter. JPMorgan Chase & Co. now owns 33,189 shares of the company’s stock valued at $739,000 after purchasing an additional 3,115 shares in the last quarter. Finally, Alps Advisors Inc. purchased a new position in Y-mAbs Therapeutics in the second quarter valued at about $1,637,000. 32.06% of the stock is currently owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

See Also: What is Blockchain?

Get a free copy of the Zacks research report on Y-mAbs Therapeutics (YMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.